Overview

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

Status:
Terminated
Trial end date:
2019-01-11
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate